MLL3 is a de novo cause of endocrine therapy resistance

ConclusionsOur data show that a decrease in functional MLL3  leads to endocrine therapy resistance. This highlights the importance of genotyping patient tumor samples forMLL3 mutation upon initial resection, prior to deciding upon treatment plans.

Source: Cancer Medicine - September 28, 2021 Category: Cancer & Oncology Authors: Kimberly M. Stauffer, David L. Elion, Rebecca S. Cook, Thomas Stricker Tags: RESEARCH ARTICLE Source Type: research